; P=0.0001). Overall mortality was n=49 (16%) and n=67 (22%) for patients in the POS and standard azo[e groups, respectively (P = 0.048).
caused by susceptible Gram-positive bacteria, including methici [[in-resistant Staphylococcus aureus (MRSA) . Clinical data in pediatric patients is limited. Methods: A retrospective chart review of pediatric patients (<18y) who received >2 doses of daptomycin between 8/2003 and 11/2006 was performed. Results: Eleven infections [9 Gram-positive bacteremias (GPB) and 2 SSTIs] in 10 patients (7 male, 3 female) were treated with daptomycin (eight received 6 mg/kg/day and three -4 mg/kg/day). Seven patients had hematological malignancies (5 ALL, 1 AML, 1 CML) and a[[ were a[[ogeneic transplant recipients. Two patients had solid tumors (neurob[astoma-1 and lung cancer-I). Median age was 11 years (range, 2-18 HematoLogy pts who had tunneLLed polyurethane CVC inserted during hospital stay for chemotherapy were randomized to 70% ethanol Lock or placebo (NaC[ 0.9%). Lumina were Locked for 15rain/day during hospitaLization and 1 ×/week otherwise. EthanoL/pLacebo was flushed sLowLy through the CVC afterwards. Liver enzymes (g-GT, ASAT) and MCV on cl0 and d14 were measured and pts were asked to fiLL out a questionary on side effects. Recruitment of 440 pts is ongoing. This abstract reports on a planned
